ArticleNature2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03177187 (ACE), which is not on this map. Cited by 89 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 1 pooled it
25.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ACE: Proof of Concept Phase I/II Trial of the CXCR2 Antagonist AZD5069, Administered in Combination With Enzalutamide, in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Novel Therapeutic Strategies for Metastatic Prostate Cancer Care.European urology · 2025Pooled it
- CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.Investigational new drugs · 2024Trial
- Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer.Oncogene · 2026Article
- Mechanisms of systemic immune modulation in tumor development: Interactions across lymph nodes, bone marrow, and blood.Cancer metastasis reviews · 2026Review
- Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.Cancer discovery · 2026Article
- KMT9 drives T cell exclusion and dysfunction by promoting PMN-MDSCs infiltration and ARG1 expression in prostate cancer.Molecular cancer · 2026Article
- Castration-resistant prostate cancer as an adaptive tumor ecosystem: coupling tumor evolution with microenvironmental reprogramming.Cancer metastasis reviews · 2026Review
- Leveraging Microphysiological Systems to Facilitate Neutrophil-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression.Nature cancer · 2026Article
- Neutrophils in cancer.Nature reviews. Cancer · 2026Review
- Biophysical reprogramming of immunosuppressive neutrophils by cold atmospheric plasma reinvigorates antitumor immunity.Science advances · 2026Article
- A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.Investigational new drugs · 2026Article
- LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer.Cancer discovery · 2026Article
- Harnessing myeloid cell plasticity for cancer therapy.Nature cancer · 2026Review
- C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions.Cancer pathogenesis and therapy · 2026Review
- Therapy-induced remodeling of the tumor immune microenvironment: Mechanistic insights and implications for immunotherapy.Chinese medical journal · 2026Review
- HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer.Cell death & disease · 2026Article
- Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer.Molecular oncology · 2026Review
- Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.Science advances · 2026Article
- Challenges and advances in drug resistance and tolerance in cancer.Journal of experimental & clinical cancer research : CR · 2026Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors at 7 institutions in 4 countries.
Christina Guo *The Institute of Cancer Research, London, UK.
Adam Sharp *The Institute of Cancer Research, London, UK.
Bora GurelThe Institute of Cancer Research, London, UK.ORCID 0000-0002-5018-8078
Mateus CrespoThe Institute of Cancer Research, London, UK.ORCID 0000-0003-4043-8296
Ines FigueiredoThe Institute of Cancer Research, London, UK.
Suneil JainNorthern Ireland Cancer Centre, Belfast, UK.
Ursula VoglOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Jan RekowskiThe Institute of Cancer Research, London, UK.ORCID 0000-0002-5207-3864
Mahtab RouhifardThe Institute of Cancer Research, London, UK.
Lewis GallagherThe Institute of Cancer Research, London, UK.ORCID 0000-0003-2694-3157
Wei YuanThe Institute of Cancer Research, London, UK.
Suzanne CarreiraThe Institute of Cancer Research, London, UK.ORCID 0000-0002-5077-5379
Khobe ChandranThe Institute of Cancer Research, London, UK.
Alec PaschalisThe Institute of Cancer Research, London, UK.
Ilaria ColomboOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.ORCID 0000-0002-0602-8667
Anastasios StathisOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.
Claudia BertanThe Institute of Cancer Research, London, UK.
George SeedThe Institute of Cancer Research, London, UK.ORCID 0000-0002-1105-1781
Jane GoodallThe Institute of Cancer Research, London, UK.
Florence RaynaudThe Institute of Cancer Research, London, UK.ORCID 0000-0003-0957-6279
Ruth RuddleThe Institute of Cancer Research, London, UK.ORCID 0000-0003-0025-8872
Karen E SwalesThe Institute of Cancer Research, London, UK.ORCID 0000-0002-6572-1293
Jason MaliaThe Institute of Cancer Research, London, UK.
Denisa BogdanThe Institute of Cancer Research, London, UK.ORCID 0000-0002-3017-4832
Crescens TiuThe Institute of Cancer Research, London, UK.ORCID 0000-0002-0515-6130
Reece CaldwellThe Royal Marsden NHS Foundation Trust, London, UK.
Caterina AversaThe Royal Marsden NHS Foundation Trust, London, UK.
Ana FerreiraThe Institute of Cancer Research, London, UK.
Antje NeebThe Institute of Cancer Research, London, UK.
Nina TunariuThe Royal Marsden NHS Foundation Trust, London, UK.
Daniel WestabyThe Institute of Cancer Research, London, UK.
Juliet CarmichaelThe Institute of Cancer Research, London, UK.
Maria Dolores Fenor de la MazaThe Institute of Cancer Research, London, UK.
Christina YapThe Institute of Cancer Research, London, UK.ORCID 0000-0002-6715-2514
Ruth MatthewsThe Institute of Cancer Research, London, UK.
Hannah BadhamThe Institute of Cancer Research, London, UK.
Toby ProutThe Institute of Cancer Research, London, UK.
Alison TurnerThe Institute of Cancer Research, London, UK.
Mona ParmarThe Institute of Cancer Research, London, UK.ORCID 0000-0001-7818-4100
Holly ToveyThe Institute of Cancer Research, London, UK.
Ruth RiisnaesThe Institute of Cancer Research, London, UK.
Penny FlohrThe Institute of Cancer Research, London, UK.
Jesus GilMRC London Institute of Medical Sciences (LMS), London, UK.ORCID 0000-0002-4303-6260
David WaughPatrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.
Shaun DecordovaThe Institute of Cancer Research, London, UK.
Anna SchlagThe Institute of Cancer Research, London, UK.
Bianca CalìInstitute of Oncology Research, Bellinzona, Switzerland.
Andrea AlimontiOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.ORCID 0000-0002-9362-2313
Johann S de BonoThe Institute of Cancer Research, London, UK. johann.debono@icr.ac.uk.ORCID 0000-0002-2034-595X
Institute of Cancer Research · GBRoyal Marsden NHS Foundation Trust · GBEnte Ospedaliero Cantonale · CHQueen's University Belfast · GBBoard of the Swiss Federal Institutes of Technology · CHInstitute of Oncology Research · CHMRC London Institute of Medical Sciences · GB
Funding
Cancer Research UK 28647Medical Research Council MC_U120085810Medical Research Council MR/M018318/1Medical Research Council MR/W018217/1Wellcome Trust
Abstract
Inflammation is a hallmark of cancer
Indexed as
Androgen Receptor AntagonistsAntineoplastic AgentsChemotaxisDrug Resistance, NeoplasmMyeloid CellsProstatic Neoplasms, Castration-ResistantBenzamidesCD11b AntigenDisease ProgressionHumansInflammationLewis X AntigenLipopolysaccharide ReceptorsMaleNeoplasm MetastasisNitrilesAndrogen Receptor AntagonistsAntineoplastic AgentsBenzamidesCD11b AntigenCD14 protein, humanenzalutamideITGAM protein, humanLewis X AntigenLipopolysaccharide ReceptorsN-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamideNitrilesPhenylthiohydantoinPyrimidinesReceptors, AndrogenSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03177187ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.